dc.contributor.author | Aarts, AMWM | en_US |
dc.contributor.author | Duffy, SW | en_US |
dc.contributor.author | Geurts, SME | en_US |
dc.contributor.author | Vulkan, DP | en_US |
dc.contributor.author | Houssami, N | en_US |
dc.contributor.author | Zappa, M | en_US |
dc.contributor.author | Nagtegaal, ID | en_US |
dc.contributor.author | Verbeek, ALM | en_US |
dc.contributor.author | Broeders, MJM | en_US |
dc.date.accessioned | 2020-05-28T15:25:57Z | |
dc.date.available | 2019-03-07 | en_US |
dc.date.issued | 2019-06 | en_US |
dc.identifier.issn | 0960-9776 | en_US |
dc.identifier.uri | https://qmro.qmul.ac.uk/xmlui/handle/123456789/64452 | |
dc.format.extent | 70 - 74 | en_US |
dc.language.iso | en | en_US |
dc.relation.ispartof | BREAST | en_US |
dc.rights | All rights reserved | |
dc.subject | Second primary breast cancer | en_US |
dc.subject | Preclinical detectable phase | en_US |
dc.subject | Test sensitivity | en_US |
dc.subject | Mammography | en_US |
dc.subject | Clinical breast examination | en_US |
dc.title | Towards evidence-based follow-up intervals for breast cancer survivors: Estimates of the preclinical detectable phase of contralateral second breast cancer | en_US |
dc.type | Article | |
dc.rights.holder | 2019 Elsevier Ltd. | |
dc.identifier.doi | 10.1016/j.breast.2019.03.003 | en_US |
pubs.author-url | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000465411900012&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=612ae0d773dcbdba3046f6df545e9f6a | en_US |
pubs.notes | Not known | en_US |
pubs.publication-status | Published | en_US |
pubs.volume | 45 | en_US |
rioxxterms.funder | Default funder | en_US |
rioxxterms.identifier.project | Default project | en_US |